STOCK TITAN

PCVX (NASDAQ: PCVX) affiliate plans sale of 2,500 shares via option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

PCVX notice of proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. The filing lists shares outstanding of 143,920,361 as of 03/11/2026. It also records a prior sale of 11,623 shares on 12/23/2025 for $556,971.85.

Positive

  • None.

Negative

  • None.

Insights

Form 144 records a small option-derived sale and prior dispositions.

The filing documents an intended sale of 2,500 common shares by exercise of stock options on 03/11/2026. It identifies the method as cash and shows an issuer-side transaction type.

Shares outstanding are reported as 143,920,361 as of 03/11/2026, giving scale context; prior reported sale was 11,623 shares on 12/23/2025. Cash-flow treatment and any transfer restrictions are not detailed in the excerpt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does PCVX's Form 144 report?

The filing reports a proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. It also lists prior sales of 11,623 shares on 12/23/2025 for $556,971.85.

Who appears to have sold shares in the prior transaction?

The excerpt attributes the prior sale to Elvia Cowan, showing 11,623 shares sold on 12/23/2025 for $556,971.85. The filing text supplies the seller name and sale amount.

How large is the proposed sale relative to outstanding shares for PCVX?

The proposed sale is 2,500 shares versus reported outstanding shares of 143,920,361 as of 03/11/2026. The filing provides these counts but does not compute percentages or dilution.

Does the Form 144 indicate who receives proceeds from the sale?

The excerpt shows the sale method as an exercise of stock options with cash indicated, but it does not explicitly state which party receives proceeds beyond the transaction method shown in the filing.
Vaxcyte, Inc.

NASDAQ:PCVX

View PCVX Stock Overview

PCVX Rankings

PCVX Latest News

PCVX Latest SEC Filings

PCVX Stock Data

8.28B
142.95M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SAN CARLOS